How to interpret results of the HEART2D trial?

Diabetes Research and Clinical Practice

Volumn 86, Issue SUPLL.1, 2009, Pages

  Tkáč, Ivan ^a   Milićević, Zvonko ^b   Jermendy, György ^c  

^a L PASTEUR UNIVERSITY HOSPITAL   (Slovakia)

^b Eli Lilly Regional Operations   (Austria)

^c BAJCSY ZSILINSZKY HOSPITAL   (Hungary)

Author keywords

Cardiovascular disease; Glucose lowering treatment; HEART2D study; Type 2 diabetes mellitus

Indexed keywords

HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DRUG EFFICACY; EVENING DOSAGE; GLYCEMIC CONTROL; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MICROALBUMINURIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PROGNOSIS; RISK REDUCTION;

EID: 72049110249     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(09)70010-5     Document Type: Article

References (12)

1. Milicevic Z., Raz I., Strojek K., Skrha J., Tan M.H., Wyatt J.W., et al. HEART2D Study. Hyperglycemia and its effect after acute myocardial infarction on cardiovascular outcomes in patients with Type 2 diabetes mellitus (HEART2D) study design. J Diabetes Complications 19 (2005) 80-87
2. Raz I., Wilson P.W.F., Strojek K., Kowalska I., Bozikov V., Gitt A.K., et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 32 (2009) 381-386
3. DECODE Study Group, and the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161 (2001) 397-405
4. Meigs J.B., Nathan D.M., D'Agostino Sr. R.B., and Wilson P.W. Framingham Offspring Study. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 25 (2002) 1845-1850
5. Hanefeld M., Fischer S., Julius U., Schulze J., Schwanebeck U., Schmechel H., et al. Risk factors for myocardial infarction and death in newly detected IDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia (1996) 1577-1583
6. Cavalot F., Petrelli A., Traversa M., Bonomo K., Fiora E., Conti M., et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 91 (2006) 813-819
7. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein H.C., Miller M.E., Byington R.P., Goff Jr. D.C., Bigger J.T., Buse J.B., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008) 2545-2559
8. Duckworth W., Abraira C., Moritz T., Reda D., Emannele N., Reaven P.D., et al., VADT Investigators. Intensive glucose control and complications in American veterans with type 2 diabetes. N Engl J Med 360 (2009) 129-139
9. ADVANCE Collaborative Group, Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008) 2560-2572
10. 1c with cardiovascular disease and mortality in adults: The European Prospective Investigation into Cancer in Norfolk. Ann Intern Med 141 (2004) 413-420
11. Malmberg K., Rydén L., Wedel H., Birkelan K., Bootsma A., Dickstein K., et al. DIGAMI Investigators. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI2): effects on mortality and morbidity. Eur Heart J 26 (2005) 650-661
12. Monnier L., and Colette C. Contributions of fasting and postprandial glucose to hemoglobin A1c. Diabetes Care 26 (2003) 881-885